ALMS

AI Memo

Alumis

As of 2026-09-03/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

—

Key catalyst

Psoriasis NDA filing targeted for Q4 2026 • 2026-12-02

Base target: $15 / p=50% prob

Biggest risk

Failure in the overall SLE population undermines the broad lupus thesis. A biomarker-selected Phase 3 strategy requires regulatory support and replication, while psoriasis approval and commercialization remain unproven after the sharp repricing.

Invalidation

Break below $6 or thesis failure.

What would change my mind?

The IFNGS-high subgroup showed robust efficacy across the primary BICLA endpoint and key secondary measures, with pharmacodynamic target engagement and no new safety signals. The psoriasis Phase 3 package and planned NDA filing provide a separate recovery path [#SEC-8K-2026-09-01].

Research note

Recommendation

—

Confidence

high

As of

2026-09-03

Base target

$15

p=50%

Bull target

$28

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

LUMUS failed overall-population endpoints
Psoriasis-only recovery path
The IFNGS-high subgroup showed robust efficacy across the primary BICLA endpoint and key secondary measures, with pharmacodynamic target engagement and no new safety signals.

BearKey bullets

An NDA filing does not ensure FDA acceptance, approval, labeling, or commercial uptake in psoriasis.
LUMUS missed primary and secondary endpoints in the overall SLE population.
Portfolio prioritization, capital allocation, and potential strategic alternatives remain uncertain.

WatchKey bullets

Psoriasis NDA filing targeted for Q4 2026

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $15 (p=50%)

Target spread vs base: +87% / -60%

Scenario probabilities

Bull Target: $28 (p=20%)Base Target: $15 (p=50%)Bear Target: $6 (p=30%)

Commentary

News tone is strongly negative following the overall-population LUMUS miss and sharp price decline. Primary company materials preserve a narrower positive case through the IFNGS-high subgroup, psoriasis efficacy, and the Q4 2026 NDA plan, but forward visibility is materially weaker and analyst reaction data is incomplete. This is a monitoring-oriented, high-volatility setup rather than a high-conviction recovery call [#SEC-8K-2026-09-01].

As of 2026-09-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

LUMUS failed overall-population endpoints
Psoriasis-only recovery path

Scenarios

Bull Target (Scenario probability)

$28 / p=20% prob

Base Target (Scenario probability)

$15 / p=50% prob

Bear Target (Scenario probability)

$6 / p=30% prob

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.90

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-02
Psoriasis NDA filing targeted for Q4 2026
Alumis reaffirmed that it remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026 [#SEC-8K-2026-09-01].
Prob 75.00% • Move 25.00% • Priced-in 45.00%
EVENT2026-12-02
Regulatory engagement on biomarker-defined SLE development
The company reported robust responses in the prespecified IFNGS-high subgroup and plans to engage regulators regarding potential Phase 3 development, but the timing and regulatory outcome remain uncertain [#SEC-8K-2026-09-01].
Prob 40.00% • Move 30.00% • Priced-in 15.00%

Short-term Catalysts

Next few weeks

LUMUS failed overall-population endpoints
2026-09-01
The Phase 2b LUMUS trial did not meet its primary or secondary endpoints in the overall SLE population, triggering an approximately 57%-58% selloff and sharply weakening the near-term thesis [#SEC-8K-2026-09-01].
Prob 100% • Move -55% • Priced-in 100%

Long-term Catalysts

Months to a year

Psoriasis-only recovery path
2027-09-03
ONWARD3 reported 54% PASI 100 response at 48 weeks, preserving a potential psoriasis-led value case despite the SLE setback [#SEC-8K-2026-08-13].
Prob 55% • Move 60% • Priced-in 30%

Risks

An NDA filing does not ensure FDA acceptance, approval, labeling, or commercial uptake in psoriasis.
LUMUS missed primary and secondary endpoints in the overall SLE population.
Portfolio prioritization, capital allocation, and potential strategic alternatives remain uncertain.
The IFNGS-high subgroup thesis may not receive regulatory support or replicate in a later Phase 3 trial.
The stock remains highly volatile after the approximately 57%-58% post-result decline.

Peers

Symbol	Summary
ARQT	Dermatology-biotech peer with more commercial footing; useful for framing how psoriasis assets may trade as launch expectations develop.
CLDX	Near-cap same-sector clinical biotech candidate, but with limited direct read-across to Alumis’s TYK2 and psoriasis programs.
IOVA	Near-cap same-sector biotech candidate; valuation comparison is loose because its development and commercial profile differs materially.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-03

Loading AI feed…

Symbol

Summary

ARQT

Dermatology-biotech peer with more commercial footing; useful for framing how psoriasis assets may trade as launch expectations develop.

CLDX

Near-cap same-sector clinical biotech candidate, but with limited direct read-across to Alumis’s TYK2 and psoriasis programs.

IOVA

Near-cap same-sector biotech candidate; valuation comparison is loose because its development and commercial profile differs materially.